Novo Nordisk A-S

Novo Nordisk A-S

Yahoo Finance • 20 hours ago

Jim Cramer Says Hold on to Moderna (MRNA) After Phase 3 Cancer Trial

On the August 26 episode of Mad Money, a caller mentioned that they had purchased 1,000 shares of Moderna, Inc. (NASDAQ:MRNA) at $54 a couple of weeks prior, watched the price go up to $150, and asked what they should do. Jim Cramer replie... Full story

Yahoo Finance • 23 hours ago

Novo's Wegovy Pill Enters China Behind Lilly

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish diabetes and obesity-treatment giant, advanced oral Wegovy into Chinese regulatory review Thursday as its shares traded at $45.88. Reuters reported that regulat... Full story

Yahoo Finance • yesterday

Mounjaro Just Opened a Much Bigger Door

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials) just gave its biggest drug another reason to keep growing. Warning! GuruFocus has detected 4 Warning Signs with NVDA. Is LLY fairly valued? Test your thesis wi... Full story

Yahoo Finance • 2 days ago

Accenture Stock And 2 Dividend Compounders for Passive Income

Central banks across Asia and Europe are moving toward tighter policy as inflation stays on the radar, yet cash in the bank still offers limited income. That gap creates a clear opening for investors who want income that can keep working e... Full story

Yahoo Finance • 2 days ago

Novo Nordisk (NVO) Stock May Be Cheap As GLP 1 Legal Risks Shift

Novo Nordisk stock has given investors a difficult few years, with the share price down about 47.0% over the past three years, yet the broader valuation checks currently lean cheap rather than expensive. That contrast is drawing attention... Full story

Yahoo Finance • 2 days ago

Novo Nordisk Could Be 54% Undervalued On Obesity Drug Setbacks

Deutsche Bank's downgrade of Novo Nordisk (NVO) to Sell, following mixed second quarter results and obesity drug setbacks, has sharpened investor focus on the stock's recent performance and current valuation. At a share price of US$47.19,... Full story

Yahoo Finance • 2 days ago

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip

Investing.com -- Deutsche Bank downgraded Novo Nordisk (NYSE:NVO) (CSE:NOVOb) to Sell from Hold and cut its price target by 9% to 265 Danish crowns from 290 crowns, flagging persisting concerns over the company's growth trajectory. The sto... Full story

Yahoo Finance • 2 days ago

Eli Lilly Finds Bigger Weight-Loss Drug Opportunity

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) is giving investors a potentially important new argument for broader Zepbound coverage: the blockbuster obesity drug may offset a meaningful portion of its cost by reducing ot... Full story

Yahoo Finance • 2 days ago

Market Chatter: Novo Nordisk Reports China Regulators Accept Weight-Loss Drug Application

Novo Nordisk (NVO) said Thursday that China's National Medical Products Administration has accepted PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 days ago

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 days ago

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as notable companies in the obesity and metabolic disease space, both focused on the growing opportunity in GLP-1 therapies. Novo Nordisk is a global leader in the category, ma... Full story

Yahoo Finance • 3 days ago

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal

Billionaire Stanley Druckenmiller, who runs the Duquesne Family Office hedge fund, has been loading up on healthcare stocks. A year ago, healthcare stocks represented almost 22% of the fund's portfolio. Today, that representation is up to... Full story

Yahoo Finance • 4 days ago

LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?

Eli Lilly LLY and AbbVie ABBV are leading U.S. drugmakers with established portfolios, blockbuster therapies, robust R&D pipelines, large market capitalizations and a strong global presence. Both have significant exposure to major therapeu... Full story

Yahoo Finance • 4 days ago

Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush

Quick Read LLY posted 48% revenue growth and controls 6 in 10 U.S. obesity prescriptions, while NVO cut 12,000 employees and saw gross margins fall to 78%. Retatrutide hit Phase 3 endpoints with weight loss approaching bariatric surgery l... Full story

Yahoo Finance • 5 days ago

Novo Resources Releases Updated Corporate Presentation

Novo Resources Corp. PERTH, Western Australia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now... Full story

Yahoo Finance • 5 days ago

Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars

On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide. It is an experimental obesity drug still in Phase 3 trials and... Full story

Yahoo Finance • 5 days ago

Is the Weight-Loss Drug Market Really a Winner-Take-All Fight Between Novo Nordisk (NVO) and Eli Lilly (LLY)?

On August 13, 2026, Novo Nordisk A/S (NYSE:NVO) CEO Mike Doustdar told Reuters that investors are underestimating how much the obesity drug market will fragment as new treatments arrive. He pushed back on the idea that Novo and Eli Lilly a... Full story

Yahoo Finance • 5 days ago

Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development... Full story

Yahoo Finance • 5 days ago

Eli Lilly Has a $100 Billion Revenue Story in the Making, 18% Upside Ahead

Quick Read LLY carries a BUY rating and $1,480 price target as $87 billion FY2026 guidance puts a $100 billion revenue milestone within reach. NVO trades at $156 billion, which is one-seventh of LLY's market cap despite a comparable GLP-1... Full story